Biolase (BIOL) Misses Q3 EPS by 156c

Biolase (NASDAQ: BIOL) reported Q3 EPS of ($3.89), $1.56 worse than the analyst estimate of ($2.33). Revenue for the quarter came in at $10.92 million versus the consensus estimate of $15.52 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49